CARLSBAD, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine”) (TSXV: ASG) (OTCQB: ASAPF), a leader in minimally invasive spine and interventional pain solutions, today announced the launch Aurora Biologixa new division dedicated to advancing spinal fusion success through best-in-class biologic innovation.
The creation of Aurora Biologics ensures seamless synergy across Aurora's growing spine ecosystem, including its renowned interspinous, lumbar and sacroiliac fusion systems such as Spare parts™, Hydra AERO™, DEXA™And SiLO™ portfolios. These mechanical and regenerative technologies are now combined into one integrated platform designed to improve patient outcomes, enhance surgical efficiency and ensure long-term fusion integrity.
Integrated biological solutions
Aurora Biologics presents a complete set solutions for allograftsincluding:
- TURBO FUSE™ Fiber Putty – A bone graft substitute consisting of demineralized bone fibers that increase surface area and promote cell attachment.
- OSTEO GRAFT™ DBM Putty – demineralized cortical bone graft with a cohesive, plastic consistency to support bone formation without synthetic carriers.
- OSTEO BRIDGE™ Sponge Strips – A sponge-like bone graft substitute that conforms to the patient's anatomy and fills bone voids to support structural regeneration.
Each biological product consists of 100% bone allograftFree of synthetic carriers, it has natural osteoconductive and osteoinductive properties for predictable and high-quality bone growth. Fully moldable and cohesive, these materials are designed to fill bone defects or augment fusion sites, providing a natural biological scaffold for bone regeneration.
Designed to work synergistically with Aurora implant technologies, the Aurora Biologics line creates complex, biologically active thermonuclear environment This optimizes outcomes for both patients and surgeons.
Executive Comment
“Aurora Biologics completes our strategy of providing clients with a holistic, fully integrated portfolio,” the company said. Matthew Goldstonecommercial director of Aurora Spine. “Each of our mechanical fusion systems – lumbar, SI or cervical – is designed to stimulate bone growth. With the addition of Aurora Biologics, we are now also improving the healing phase, allowing surgeons to perform a fully optimized fusion procedure from start to finish.”
“Our new Aurora Biologics platform not only strengthens our commitment to improving clinical outcomes, but also serves as a powerful catalyst for growth,” the company said. Trent J. NorthcuttPresident and CEO of Aurora Spine. “By integrating biologics into our portfolio of minimally invasive products, we expect greater than 30 percent growth over previous biologics offerings, resulting in increased revenue and creating a powerful new revenue stream for Aurora Spine.”
Setting a new standard in spine care
Aurora Spine believes that the arrival of Aurora Biologics will set a new standard for the effectiveness of biologics in spine treatment. In accordance with the company philosophy “Simplification of the complex.” These products are designed to be best-in-class: easy to use, clinically effective, and backed by Aurora Spine's unwavering commitment to innovation and quality.
About Aurora Spine
Aurora Spine Corporation (TSXV: ASG) (OTCQB: ASAPF) is an innovative developer and manufacturer of minimally invasive spinal implants and interventional pain management technologies. Headquartered in Carlsbad, California, the company's mission is to improve spine surgery outcomes through simplified, integrated and cost-effective solutions that improve patient care worldwide.
For more information, visit www.aurora-spine.com or www.aurorapaincare.com. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This press release contains statements that constitute “forward-looking information” within the meaning of applicable Canadian securities legislation and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). Forward-looking statements include, but are not limited to, statements regarding the expected results, commercial success or market acceptance of Aurora Biologics' product line; expected revenue growth or margin improvement; and the company's plans, goals, expectations or intentions.
Forward-looking statements are based on management's current expectations and assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in the regulatory environment, competitive conditions, demand for the Company's products and other risks, which are detailed from time to time in Aurora Spine's public filings with securities regulators.
Readers are cautioned not to place undue reliance on forward-looking statements. Aurora Spine undertakes no obligation to update or revise any forward-looking statements except as required by applicable securities laws.
Contacts of the company and investor
Aurora Spine Corporation
Trent Northcutt
President and CEO
Telephone: (760) 424-2004
Chad Klaus
Financial Director
Telephone: (760) 424-2004
Website: www.aurora-spine.com
Investor Relations
Adam Lowensteiner
Leatham Partners
Telephone: (646) 829-9702
E-mail: [email protected]
